The company's future now appears to be in flux, as simufilam was its only drug in clinical trials, The New York Times reported. Also: a Roche lung cancer drug has failed to improve survival; pharma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback